BC Week In Review | Apr 28, 2017
Company News

Epigenomics, Cathay Fortune deal

Cathay's Blitz F16-83 GmbH subsidiary will acquire molecular diagnostics company Epigenomics for €7.52 per share, or about €171 million ($185.6 million) in cash. The price is a 52% premium on Epigenomics' closing price of €4.95...
BC Extra | Apr 26, 2017
Company News

Chinese PE firm to acquire Epigenomics

A subsidiary of Chinese private equity firm Cathay Fortune International Co. Ltd. will acquire molecular diagnostics company Epigenomics AG (Xetra:ECX; OTCQX:EPGNY) for €7.52 per share, or about €171 million ($185.6 million) in cash. The subsidiary,...
BC Extra | Jul 28, 2016
Financial News

Exact Sciences raises $131.8M in follow-on

Exact Sciences Corp. (NASDAQ:EXAS) raised $131.8 million through the sale of 8.5 million shares at $15.50 in a bumped-up follow-on underwritten by Jefferies, Baird and Canaccord Genuity. The company had proposed after market close Wednesday...
BC Extra | Jul 26, 2016
Financial News

Exact Sciences gains as Cologuard revenues grow

Exact Sciences Corp. (NASDAQ:EXAS) gained $3.75 (30%) to $16.21 on Tuesday after reporting 2Q16 revenues of colorectal cancer test Cologuard that beat expectations, and a narrower than expected loss per share in the quarter. Revenues...
BC Week In Review | Aug 24, 2015
Company News

Epigenomics, BioChain Institute sales and marketing update

Epigenomics said the Chinese Guideline on Screening, Endoscopic Diagnosis and Treatment of Early Colorectal Cancer (CRC) recommended plasma Septin9 gene DNA methylation assay (mSEPT9) as a standard test for early CRC screening. Epi proColon, a...
BC Week In Review | May 18, 2015
Clinical News

Epi proColon: Clinical trial data

The U.S. ADMIT trial in 413 average-risk patients ages 50-76 who have been historically non-compliant to colorectal cancer screening according to screening guidelines showed a 99.5% rate of adherence to colorectal cancer screening using Epigenomics’...
BC Week In Review | Apr 13, 2015
Company News

Exact Sciences Corp, Ironwood deal

The companies will co-promote Exact’s colorectal cancer test Cologuard in the U.S. under a one-year, non-exclusive deal, which can be extended. Cologuard is a non-invasive stool DNA test that utilizes a multiplexed quantitative Invader assay...
BC Week In Review | Mar 30, 2015
Clinical News

Epi proColon: Clinical trial completed enrollment

Epigenomics completed enrollment of about 420 average-risk patients ages 50-76 that have been historically non-compliant to colorectal cancer screening according to screening guidelines in the U.S. ADMIT trial comparing Epi proColon vs. fecal immunochemical test...
BC Week In Review | Jan 12, 2015
Clinical News

Epi proColon: Clinical trial started

Epigenomics began the U.S. ADMIT trial to compare Epi proColon vs. fecal immunochemical test (FIT) in about 420 average-risk patients ages 50-76 years that have been historically non-compliant to colorectal cancer screening according to screening...
BC Extra | Dec 9, 2014
Company News

China approves Epigenomics' colon cancer test

Epigenomics AG (Xetra:ECX; OTCQX:EPGNY) jumped EUR 1.03 (23%) to EUR 5.53 on Monday after China FDA approved the company's Epi proColon 2.0 non-invasive, blood-based diagnostic test for colorectal cancer. Epigenomics said partner BioChain Institute Inc....
Items per page:
1 - 10 of 40